Ken Griffin Viking Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,097,300 shares of VKTX stock, worth $26.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,097,300

Previous 1,319,600 16.85%

Holding current value

$26.3 Million

Previous $31.9 Million 8.75%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$19.98 - $29.49 $15.5 Million - $22.9 Million	-778,115 Reduced 47.13%	872,975 $23.1 Million
Q1 2025 May 15, 2025	BUY	$24.15 - $42.89 $4.01 Million - $7.12 Million	166,011 Added 11.18%	1,651,090 $39.9 Million
Q4 2024 Feb 14, 2025	BUY	$38.28 - $78.03 $474,786 - $967,806	12,403 Added 0.84%	1,485,079 $59.8 Million
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $50.1 Million - $70.9 Million	1,006,198 Added 215.7%	1,472,676 $93.2 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $20.6 Million - $34.9 Million	-435,271 Reduced 48.27%	466,478 $24.7 Million
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $14.4 Million - $78.5 Million	830,182 Added 1160.01%	901,749 $73.9 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $661,279 - $1.41 Million	71,567 New	71,567 $1.33 Million
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $882,609 - $1.47 Million	-59,475 Reduced 39.86%	89,717 $1.45 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $1.01 Million - $2.17 Million	125,236 Added 522.78%	149,192 $2.48 Million
Q4 2022 Feb 14, 2023	SELL	$2.72 - $9.4 $76,951 - $265,935	-28,291 Reduced 54.15%	23,956 $225,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $172,387 - $262,975	-67,603 Reduced 56.41%	52,247 $143,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $1.04 Million - $1.55 Million	-491,795 Reduced 80.41%	119,850 $347,000
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $1.05 Million - $1.7 Million	348,646 Added 132.57%	611,645 $1.84 Million
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $639,188 - $933,770	138,954 Added 112.02%	262,999 $1.21 Million
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $330,810 - $417,366	-59,285 Reduced 32.34%	124,045 $779,000
Q2 2021 Aug 16, 2021	BUY	$5.19 - $6.73 $579,364 - $751,276	111,631 Added 155.69%	183,330 $1.1 Million
Q1 2021 May 17, 2021	SELL	$5.74 - $9.67 $1.1 Million - $1.86 Million	-192,071 Reduced 72.82%	71,699 $454,000
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $702,440 - $889,316	132,536 Added 100.99%	263,770 $1.49 Million
Q3 2020 Nov 16, 2020	BUY	$5.73 - $8.11 $231,640 - $327,854	40,426 Added 44.52%	131,234 $763,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $302,760 - $562,368	69,600 Added 328.18%	90,808 $655,000
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $54,865 - $126,428	-15,903 Reduced 42.85%	21,208 $99,000
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $7.95 Million - $11 Million	-1,036,463 Reduced 96.54%	37,111 $308,000
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $576,299 - $755,728	76,029 Added 7.62%	1,073,574 $0
Q4 2018 Feb 14, 2019	BUY	$7.16 - $16.21 $342,563 - $775,551	47,844 Added 5.04%	997,545 $7.63 Million
Q3 2018 Nov 13, 2018	BUY	$9.7 - $19.65 $4.91 Million - $9.95 Million	506,430 Added 114.25%	949,701 $0
Q2 2018 Aug 10, 2018	BUY	$3.88 - $12.74 $1.66 Million - $5.46 Million	428,296 Added 2860.07%	443,271 $0
Q1 2018 May 11, 2018	BUY	$4.11 - $6.93 $61,547 - $103,776	14,975 New	14,975 $65,000
Q4 2017 Feb 09, 2018	SELL	$1.74 - $4.34 $98,242 - $245,040	-56,461 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$0.94 - $1.91 $53,073 - $107,840	56,461	56,461 $108,000

Others Institutions Holding VKTX

# of Institutions

454

Shares Held

68.3M

Call Options Held

7.72M

Put Options Held

3.31M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $1.84B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account